To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer

NCT03676192 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

689

Enrollment

INDUSTRY

Sponsor class

Conditions

Adenocarcinoma of Lung

Interventions

DRUG: CT-P16
DRUG: Avastin

Sponsor

Celltrion